Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, results from a recent clinica
Source: BWH News - Category: Hospital Management Source Type: news
More News: Cancer | Cancer & Oncology | Hospital Management | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer